Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.40 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.30 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrole SCHEMBL82930 | 0.87 | EGFR (0.36) | EGFR | |
| SCHEMBL16878146 | 0.82 | EGFR (0.33) | EGFRHSP90AA1 | |
| SCHEMBL1263213 | 0.73 | EGFR (0.33) | EGFRHSP90AA1 | |
| Quinoxaline SCHEMBL23530618 | 0.72 | EGFR (0.62) | EGFRPIK3CDPIK3CA | |
| Quinazoline SCHEMBL2726373 | 0.71 | EGFR (0.69) | EGFRPIK3CDPIK3CA | |
| SCHEMBL219949 | 0.71 | PKM (0.33) | — | |
| SCHEMBL127479 | 0.71 | EGFR (0.50) | EGFRRPS6KA5RPS6KA4HSP90AA1PIK3CD | |
| SCHEMBL374489 | 0.70 | EGFR (0.37) | EGFR | |
| SCHEMBL51486 | 0.70 | EGFR (0.52) | EGFRRPS6KA5PIK3CDPIK3CA | |
| SCHEMBL30148832 | 0.70 | EGFR (0.37) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2024-07-25 | — | — | US | claimed |
| EP-4242202-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-09-13 | — | — | EP | claimed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | claimed |
| CN-114763352-A | GLP-1 receptor agonist and application thereof in medicine | 海思科医药集团股份有限公司 | 2022-07-19 | — | — | CN | claimed |
| WO-2022111624-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-06-02 | — | — | WO | claimed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | claimed |
| EP-2336315-B1 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION AS (DK) | 2017-07-19 | — | — | EP | claimed |
| EP-2336315-A2 | Enzymatic encoding methods for efficient synthesis of large libraries | Nuevolution A/S (DK) | 2011-06-22 | — | — | EP | claimed |
| CN-1812792-A | Use of dipyridamole or mopidamole for the treatment and prevention of thromboembolic diseases and disorders due to overproduction of thrombin and/or increased thrombin receptor expression | BOEHRINGER INGELHEIM INT (DE) | 2006-08-02 | — | — | CN | claimed |
| US-4226863-A | BACTERICIDES, ANTIBIOTICS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-10-07 | — | — | US | claimed |
| US-4125611-A | MICROBIOCIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1978-11-14 | — | — | US | claimed |
| JP-52027794-A | — | — | None | — | — | JP | disclosed |
| WO-2025050846-A1 | COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 中山优理生物医药有限公司 | 2025-03-13 | — | — | WO | disclosed |
| EP-4219463-B1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN SALUBRIS PHARM CO LTD (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-115594669-B | Parallel ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-11-05 | — | — | CN | disclosed |
| EP-0414386-A1 | Condensed pyrimidine derivates | DowElanco (US) | 1991-02-27 | — | — | EP | disclosed |
| EP-0000382-B1 | PYRIMIDO (4,5-C)PYRIDAZINES, COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-10-06 | — | — | EP | disclosed |
| US-4226863-A | BACTERICIDES, ANTIBIOTICS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-10-07 | — | — | US | disclosed |
| US-4125611-A | MICROBIOCIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1978-11-14 | — | — | US | disclosed |
| JP-S5227794-A | PREPARATION OF SYNTHESIS OF NNACYLAMINOO ARYLACETAMIDO CEPHALOSPORIN S | SUMITOMO CHEM CO LTD | 1977-03-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GLP1R, GIPR, GCGR | EGFR 1993/4885RPS6KA5 3345/4885RPS6KA4 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.